CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZED STUDY

Trial details

Who runs it

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Trial code

EU 2024-517789-41-00

Record updated

2025. november 17.

Original description

To evaluate the effect of deferred CN on patients’ survival in those receiving standard of care (SOC) with anti-PD1-based therapies for metastatic renal cell carcinoma (mRCC)Read full original descriptionShow less

To evaluate the effect of deferred CN on patients’ survival in those receiving standard of care (SOC) with anti-PD1-based therapies for metastatic renal cell carcinoma (mRCC)

Inclusion: Informed consent obtained before any study-specific procedures. Patients must be able to understand and be willing to sign a written informed consent; Women of childbearing potential and men must agree to use adequate contraception since signing of the informed consent form until at least 3 months after the last study drug administration. The investigator or a designated associate is requested to advise the subject how to achieve an adequate birth control. Adequate contraception is defined in the study as any medically recommend method (or combination of methods) as per standard of care; Adequate bone-marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment: a) Creatinine value <2.5 mg/dl and creatinine clearance > 30 ml/min evaluated by the Cockcroft-Gault Formula. b) Total bilirubin ≤1∙5 × the upper limit of normal (ULN); c) Alanine aminotransferase and aspartate aminotransferase ≤2 × ULN (≤5 × ULN for patients with liver involvement of their cancer); d) International normalized ratio (INR) and partial thromboplastin time (PTT) ≤1∙5 × ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no prior evidence of an underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care; e) Platelet count ≥100 000/mm3, hemoglobin >9 g/dl, absolute neutrophil count >1,500/mm3; f) Alkaline phosphatase limit ≤2∙5 × ULN (≤5 × ULN for patients with liver involvement of their cancer); Male or female patient ≥18 years of age; Histological or cytological documentation of renal cell carcinoma with predominantly clear cell histology; Evidence of primary renal cancer; Measurable or not measurable metastatic disease according to Response Evaluation Criteria in Solid Tumors criteria, version 1.1; Eastern Cooperative Oncology Group performance status of ≤1; Life expectancy of at least 9 months; Under treatment with SOC consisting in one anti-PD1 based therapy among axitinib + pembrolizumab or cabozantinib + nivolumab or lenvatinib + pembrolizumab or nivolumab alone after nivolumab + ipilimumab for at least 24 but not more than 52 weeks at the time of the signed informed consent and without evidence of progressive disease based on RECIST criteria v 1.1; Eligible to continue the combination of therapies for mRCC (or nivolumab alone in case of nivolumab + ipilimumab).

Exclusion: Symptomatic metastatic brain or meningeal tumors unless the patient is >2 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also, the patient must not be undergoing acute steroid therapy or tapering (chronic steroid therapy is acceptable provided that the dose is stable for 1 month before and after screening radiographic studies); Any contraindication to surgery or radiotherapy on primary renal tumor; Discontinuation (definitive) of one of the therapies for mRCC due to toxicity (previous discontinuation of ipilimumab in the ipilimumab + nivolumab combo is allowed); Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before the signed informed consent; Pregnancy or breast-feeding. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before surgery or radiotherapy on primary tumor, and a negative result must be documented before start of treatment; Any cardiological condition among: a) Congestive heart failure of New York Heart Association class 3 or worse. b) Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of study drug. c) Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted). d) Uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic pressure >90 mmHg despite optimal medical management). e) Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), pulmonary embolism within the 4 months before start of study; Known history of human immunodeficiency (HIV) virus infection or known history of chronic hepatitis B or C; Any autoimmune reaction or toxicity that contraindicates the use of anti-PD1 therapy; Seizure disorder requiring medication; History of organ allograft; Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event of CTCAE grade 3 or higher within 4 weeks of start of study medication; Non-healing wound, ulcer, or bone fracture; Renal failure requiring hemodialysis or peritoneal dialysis; Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his or her compliance in the study; Concurrent or previous cancer within 3 years before enrolment EXCEPT curatively treated cervical cancer in situ, non-melanoma skin cancer and pT2 prostate cancer with PSA<0.01 or non-muscle invasive bladder cancer; Ongoing infection higher than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 grade 2; More than one treatment for metastatic or locally advanced renal cell carcinoma; Solitary kindney.

EU CTIS 2024-517789-41-00